2BBBullish & Bearish
Genelux Corporation (GNLX) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 26 out of 100.
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
Genelux Corporation’s current 2BB score is 26 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 7 | Very Low |
| Momentum | 44 | Stable |
| Financial strength | 23 | Weak |
| Quality | 60 | Strong |
| Risk | 46 | Moderate |
| Headquarters | Westlake Village, California, United States |
| Founded | 2001 |
| Employees | 26 |
| 52-week range | $2.29 – $8.54 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-02 | — | -0.204 | — | $0.00 |
| 2026-08-03 | — | -0.2006 | — | $0.00 |
| 2026-05-07 | -0.2 | -0.1836 | $0.00 | $0.00 |
| 2026-03-19 | -0.25 | -0.2227 | $8,000.00 | $0.00 |